

July 17, 2024

The Listing Department
BSE Limited
Phiroze Jeejebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 of SEBI Listing Regulations, we would like to inform that one of the subsidiary Company i.e., Optival Health Solutions Private Limited has received three suspension orders of Drug License for stores situated at West Bengal and Telangana. Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 details is given below:

Name(s) of the Authority	Nature and details of the action(s) taken, initiated or order(s) passed	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	violation(s)/ contravention(s) committed or alleged to be	Impact on financial operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
Directorate of Drugs Control Hooghly Dist. Drugs Control Office, West Bengal.	Suspension of Drug License of stores situated at (I). Dankuni Litchutala and (II) Dankuni Subhashpally North, Hooghly, West Bengal for Fourteen days each store.	Order Received	-	
The Assistant Director Drugs Control Administration, Nizamabad, Telangana.	Suspension of Drug License of store situated at Nirmal Main Road, Nizamabad, Telangana for one day.	on 16.7.2024	Under Rule 65(4)(4)(i) of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules 1945	Potential Revenue Loss of Rs~ 0.34 Lacs.

Kindly take the same on records.

For MedPlus Health Services Limited

Manoj Kumar Srivastava Company Secretary & Compliance Officer FCS 7460